Wall Street brokerages expect Medpace Holdings Inc (NASDAQ:MEDP) to report earnings per share of $0.38 for the current quarter, according to Zacks. Six analysts have issued estimates for Medpace’s earnings, with the highest EPS estimate coming in at $0.41 and the lowest estimate coming in at $0.37. Medpace reported earnings per share of $0.35 in the same quarter last year, which would suggest a positive year over year growth rate of 8.6%. The company is scheduled to issue its next earnings report on Monday, February 26th.
On average, analysts expect that Medpace will report full year earnings of $1.50 per share for the current financial year, with EPS estimates ranging from $1.49 to $1.52. For the next financial year, analysts expect that the firm will report earnings of $1.72 per share, with EPS estimates ranging from $1.67 to $1.84. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Medpace.
Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 30th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.04. Medpace had a net margin of 6.44% and a return on equity of 10.00%. The firm had revenue of $98.68 million for the quarter, compared to analyst estimates of $96.84 million. During the same quarter last year, the firm posted $0.40 earnings per share. Medpace’s revenue for the quarter was up 4.1% compared to the same quarter last year.
In other news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $30.16, for a total transaction of $138,736,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 25.80% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. grew its position in shares of Medpace by 0.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 28,074 shares of the company’s stock worth $815,000 after buying an additional 152 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Medpace by 1.4% during the second quarter. Goldman Sachs Group Inc. now owns 34,690 shares of the company’s stock worth $1,006,000 after buying an additional 482 shares in the last quarter. Rhumbline Advisers grew its position in shares of Medpace by 13.3% during the second quarter. Rhumbline Advisers now owns 9,726 shares of the company’s stock worth $282,000 after buying an additional 1,140 shares in the last quarter. Teachers Advisors LLC grew its position in shares of Medpace by 9.1% during the first quarter. Teachers Advisors LLC now owns 27,271 shares of the company’s stock worth $814,000 after buying an additional 2,278 shares in the last quarter. Finally, Susquehanna International Group LLP grew its position in shares of Medpace by 30.9% during the third quarter. Susquehanna International Group LLP now owns 9,947 shares of the company’s stock worth $317,000 after buying an additional 2,347 shares in the last quarter. 16.80% of the stock is owned by institutional investors and hedge funds.
Shares of Medpace (MEDP) traded up $0.29 during trading hours on Friday, reaching $35.17. 233,100 shares of the company’s stock traded hands, compared to its average volume of 187,897. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.68 and a quick ratio of 0.68. Medpace has a one year low of $21.76 and a one year high of $39.64. The firm has a market capitalization of $1,310.83, a P/E ratio of 23.73, a price-to-earnings-growth ratio of 1.79 and a beta of -0.96.
Medpace Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.